1 |
Sridhar S, Teng JLL, Chiu TH, Lau SKP, Woo PCY. 2017. Hepatitis E virus genotypes and evolution: emergence of camel hepatitis E variants. Int. J. Mol. Sci. 18: E869.
DOI
|
2 |
Pavio N, Meng XJ, Doceul V. 2015. Zoonotic origin of hepatitis E. Curr. Opin. Virol. 10: 34-41.
DOI
|
3 |
Meng XJ. 2010. Hepatitis E virus: animal reservoirs and zoonotic risk. Vet. Microbiol. 140: 256-265.
DOI
|
4 |
Tam AW, Smith MM, Guerra ME, Huang CC, Bradley DW, Fry KE, et al. 1991. Hepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genome. Virology 185: 120-131.
DOI
|
5 |
Graff J, Torian U, Nguyen H, Emerson SU. 2006. A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus. J. Virol. 80: 5919-5926.
DOI
|
6 |
Kabrane-Lazizi Y, Fine JB, Elm J, Glass GE, Higa H, Diwan A, et al. 1999. Evidence for widespread infection of wild rats with hepatitis E virus in the United States. Am. J. Trop. Med. Hyg. 61: 331-335.
DOI
|
7 |
Ropp S L, T am AW, B eames B, P urdy M , Frey TK. 2000. Expression of the hepatitis E virus ORF1. Arch. Virol. 145: 1321-1337.
DOI
|
8 |
Sehgal D, Thomas S, Chakraborty M, Jameel S. 2006. Expression and processing of the hepatitis E virus ORF1 nonstructural polyprotein. Virol. J. 3: 38.
DOI
|
9 |
Suppiah S , Zhou Y , Frey TK. 2011. Lack of processing of the expressed ORF1 gene product of hepatitis E virus. Virol. J. 8: 245.
DOI
|
10 |
Graff J, Zhou YH, Torian U, Nguyen H, St Claire M, Yu C, et al. 2008. Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles. J. Virol. 82: 1185-1194.
DOI
|
11 |
Jameel S. 1999. Molecular biology and pathogenesis of hepatitis E virus. Expert Rev. Mol. Med. 1999: 1-16.
|
12 |
Smith DB, Purdy MA, Simmonds P. 2013. Genetic variability and the classification of hepatitis E virus. J. Virol. 87: 4161-4169.
DOI
|
13 |
Yamada K, Takahashi M, Hoshino Y, Takahashi H, Ichiyama K, Nagashima S, et al. 2009. ORF3 p rotein of hepatitis E virus is essential for virion release from infected cells. J. Gen. Virol. 90: 1880-1891.
DOI
|
14 |
Qi Y, Zhang F, Zhang L, Harrison TJ, Huang W, Zhao C, et al. 2015. Hepatitis E virus produced from cell culture has a lipid envelope. PLoS One 10: e0132503.
DOI
|
15 |
Shiota T, Li TC, Yoshizaki S, Kato T, Wakita T, Ishii K. 2013. The hepatitis E virus capsid C-terminal region is essential for the viral life cycle: implication for viral genome encapsidation and particle stabilization. J. Virol. 87: 6031-6036.
DOI
|
16 |
Takahashi M, Yamada K, Hoshino Y, Takahashi H, Ichiyama K, Tanaka T, et al. 2008. Monoclonal antibodies raised against the ORF3 protein of hepatitis E virus (HEV) can capture HEV particles in culture supernatant and serum but not those in feces. Arch. Virol. 153: 1703-1713.
DOI
|
17 |
Dong C, Zafrullah M, Mixson-Hayden T, Dai X, Liang J, Meng J, et al. 2012. Suppression of interferon-alpha signaling by hepatitis E virus. Hepatology 55: 1324-1332.
DOI
|
18 |
Bode JG, Ludwig S, Ehrhardt C, Albrecht U, Erhardt A, Schaper F, et al. 2003. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 17: 488-490.
DOI
|
19 |
Shuai K, Liu B. 2003. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3: 900-911.
DOI
|
20 |
Akhtar LN, Qin H, Muldowney MT, Yanagisawa LL, Kutsch O, Clements JE, et al. 2010. Suppressor of cytokine signaling 3 inhibits antiviral IFN-beta signaling to enhance HIV-1 replication in macrophages. J. Immunol. 185: 2393-2404.
DOI
|
21 |
Boost KA, Sadik CD, Bachmann M, Zwissler B, Pfeilschifter J, Muhl H. 2008. IFN-gamma impairs release of IL-8 by IL-1beta-stimulated A549 lung carcinoma cells. BMC Cancer 8: 265.
DOI
|
22 |
Huang F, Yang C, Yu W, Bi Y, Long F, Wang J, et al. 2016. Hepatitis E virus infection activates signal regulator protein alpha to down-regulate type Iinterferon. Immunol. Res. 64: 115-122.
DOI
|
23 |
Nan Y, Yu Y, Ma Z, Khattar SK, Fredericksen B, Zhang YJ. 2014. Hepatitis E virus inhibits type I interferon induction by ORF1 products. J. Virol. 88: 11924-11932.
DOI
|
24 |
Karpe YA, Lole KS. 2011. Deubiquitination activity associated with hepatitis E virus putative papain-like cysteine protease. J. Gen. Virol. 92: 2088-2092.
DOI
|
25 |
Frias-Staheli N, Giannakopoulos NV, Kikkert M, Taylor SL, Bridgen A, Paragas J, et al. 2007. Ovarian tumor domaincontaining viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe 2: 404-416.
DOI
|
26 |
Sulea T, Lindner HA, Purisima EO, Menard R. 2005. Deubiquitination, a new function of the severe acute respiratory syndrome coronavirus papain-like protease? J. Virol. 79: 4550-4551.
DOI
|
27 |
Chen WC, Tseng CK, Chen YH, Lin CK, Hsu SH, Wang SN, et al. 2015. HCV NS5A up-regulates COX-2 expression via IL-8-mediated activation of the ERK/JNK MAPK pathway. PLoS One 10: e0133264.
DOI
|
28 |
Collins AS, Ahmed S, Napoletano S, Schroeder M, Johnston JA, Hegarty JE, et al. 2014. H epatitis C virus (HCV)-induced suppressor of cytokine signaling (SOCS) 3 regulates proinflammatory TNF-alpha responses. J. Leukoc. Biol. 96: 255-263.
DOI
|
29 |
Munir M, Zohari S, Belak S, Berg M. 2012. Doublestranded RNA-induced activation of activating protein-1 promoter is differentially regulated by the non-structural protein 1 of avian influenza A viruses. Viral Immunol. 25: 79-85.
DOI
|
30 |
Kang SM, Won SJ, Lee GH, Lim YS, Hwang SB. 2010. Modulation of interferon signaling by hepatitis C virus non-structural 5A protein: implication of genotypic difference in interferon treatment. FEBS Lett. 584: 4069-4076.
DOI
|
31 |
Devhare PB, Desai S, Lole KS. 2016. Innate immune responses in human hepatocyte-derived cell lines alter genotype 1 hepatitis E virus replication efficiencies. Sci. Rep. 6: 26827.
DOI
|
32 |
Skaug B, Chen ZJ. 2010. Emerging role of ISG15 in antiviral immunity. Cell 143: 187-190.
DOI
|
33 |
Ortiz NE, Nijhawan RI, Weinberg JM. 2013. Acitretin. Dermatol. Ther. 26: 390-399.
DOI
|
34 |
Clark K, Plater L, Peggie M, Cohen P. 2009. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation. J. Biol. Chem. 284: 14136-14146.
DOI
|
35 |
Shimada T, Kawai T, Takeda K, Matsumoto M, Inoue J, Tatsumi Y, et al. 1999. IKK-i, a novel lipopolysaccharideinducible kinase that is related to IkappaB kinases. Int. Immunol. 11: 1357-1362.
DOI
|
36 |
Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, et al. 2004. The roles of two IkappaB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J. Exp. Med. 199: 1641-1650.
DOI
|
37 |
Gale M Jr, Foy EM. 2005. Evasion of intracellular host defence by hepatitis C virus. Nature 436: 939-945.
DOI
|
38 |
Buccheri L, Katchen BR, Karter AJ, Cohen SR. 1997. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch. Dermatol. 133: 711-715.
DOI
|
39 |
Li P, Kaiser P, Lampiris HW, Kim P, Yukl SA, Havlir DV, et al. 2016. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation. Nat. Med. 22: 807-811.
DOI
|
40 |
Horner SM, Gale M Jr. 2013. Regulation of hepatic innate immunity by hepatitis C virus. Nat. Med. 19: 879-888.
DOI
|
41 |
Zhou X, Xu L, Wang W, Watashi K, Wang Y, Sprengers D, et al. 2016. Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection. J. Viral Hepat. 23: 294-304.
DOI
|
42 |
Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, et al. 2005. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6: 981-988.
DOI
|
43 |
Nair VP, Anang S, Subramani C, Madhvi A, Bakshi K, Srivastava A, et al. 2016. Endoplasmic reticulum stress induced synthesis of a novel viral factor mediates efficient replication of genotype-1 hepatitis E virus. PLoS Pathog. 12: e1005521.
DOI
|
44 |
Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124: 783-801.
DOI
|
45 |
Medzhitov R. 2007. Recognition of microorganisms and activation of the immune response. Nature 449: 819-826.
DOI
|
46 |
Seth RB, Sun L, Ea CK, Chen ZJ. 2005. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122: 669-682.
DOI
|
47 |
Xu LG, Wang YY, Han KJ, Li LY, Z hai Z, S hu H B. 2005. VISA is an adapter protein required for virus-triggered IFN-beta signaling. Mol. Cell 19: 727-740.
DOI
|
48 |
Hardy MP, McGettrick AF, O'Neill LA. 2004. Transcriptional regulation of the human TRIF (TIR domain-containing adaptor protein inducing interferon beta) gene. Biochem. J. 380: 83-93.
DOI
|
49 |
Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M Jr. 2008. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 454: 523-527.
DOI
|
50 |
Nguyen HT, Torian U, Faulk K, Mather K, Engle RE, Thompson E, et al. 2012. A naturally occurring human/ hepatitis E recombinant virus predominates in serum but not in faeces of a chronic hepatitis E patient and has a growth advantage in cell culture. J. Gen. Virol. 93: 526-530.
DOI
|
51 |
Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford JM, et al. 2007. Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 133: 1649-1659.
DOI
|
52 |
Rotondi M, Coperchini F, Chiovato L. 2013. CXCL8 in thyroid disease: from basic notions to potential applications in clinical practice. Cytokine Growth Factor Rev. 24: 539-546.
DOI
|
53 |
Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. 2003. Role of adaptor TRIF in the MyD88- independent Toll-like receptor signaling pathway. Science 301: 640-643.
DOI
|
54 |
Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. 2003. IKKepsilon a nd TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 4: 491-496.
|
55 |
Eksioglu EA, Zhu H, Bayouth L, Bess J, Liu HY, Nelson DR, et al. 2011. Characterization of HCV interactions with Toll-like receptors and RIG-I in liver cells. PLoS One 6: e21186.
DOI
|
56 |
Xu L, Zhou X, Wang W, Wang Y, Yin Y, Laan LJ, et al. 2016. IFN regulatory factor 1 restricts hepatitis E virus replication by activating STAT1 to induce antiviral IFNstimulated genes. FASEB J. 30: 3352-3367.
DOI
|
57 |
Ghasemi H, Ghazanfari T, Yaraee R, Faghihzadeh S, Hassan ZM. 2011. Roles of IL-8 in ocular inflammations: a review. Ocul. Immunol. Inflamm. 19: 401-412.
DOI
|
58 |
Pichert A, Schlorke D, Franz S, Arnhold J. 2012. Functional aspects of the interaction between interleukin-8 and sulfated glycosaminoglycans. Biomatter 2: 142-148.
DOI
|
59 |
Zarogoulidis P, Katsikogianni F, Tsiouda T, Sakkas A, Katsikogiannis N, Zarogoulidis K. 2014. Interleukin-8 and interleukin-17 for cancer. Cancer Invest. 32: 197-205.
DOI
|
60 |
Hacker H, Karin M. 2006. Regulation and function of IKK and IKK-related kinases. Sci. STKE 2006: re13.
|
61 |
Gatot JS, Gioia R, Chau TL, Patrascu F, Warnier M, Close P, et al. 2007. Lipopolysaccharide-mediated interferon regulatory factor activation involves TBK1-IKKepsilon-dependent Lys(63)-linked polyubiquitination and phosphorylation of TANK/I-TRAF. J. Biol. Chem. 282: 31131-31146.
DOI
|
62 |
Grandvaux N, Servant MJ, tenOever B, Sen GC, Balachandran S, Barber GN, et al. 2002. Transcriptional profiling of interferon regulatory factor 3 target genes: direct involvement in the regulation of interferon-stimulated genes. J. Virol. 76: 5532-5539.
DOI
|
63 |
Hiscott J. 2007. Triggering the innate antiviral response through IRF-3 activation. J. Biol. Chem. 282: 15325-15329.
DOI
|
64 |
Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. 2001. Recognition of double-stranded RNA and activation of NFkappaB by Toll-like receptor 3. Nature 413: 732-738.
DOI
|
65 |
Li Z, Chen L, Liu Q. 2015. Activation of CXCL-8 transcription by hepatitis E virus ORF-1 via AP-1. Mediators Inflamm. 2015: 495370.
|
66 |
Holtmann H, Winzen R, Holland P, Eickemeier S, Hoffmann E, Wallach D, et al. 1999. Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol. Cell. Biol. 19: 6742-6753.
DOI
|
67 |
Cucinotta M, Visalli M, Aguennouz M, Valenti A, Loddo S, Altucci L, et al. 2008. Regulation of interleukin-8 gene at a distinct site of its promoter by CCAAT enhancer-binding protein homologous protein in prostaglandin E2-treated human T cells. J. Biol. Chem. 283: 29760-29769.
DOI
|
68 |
Nozell S, Laver T, Patel K, Benveniste EN. 2006. Mechanism of IFN-beta-mediated inhibition of IL-8 gene expression in astroglioma cells. J. Immunol. 177: 822-830.
DOI
|
69 |
Gusella GL, Musso T, Bosco MC, Espinoza-Delgado I, Matsushima K, Varesio L. 1993. IL-2 up-regulates but IFNgamma suppresses IL-8 expression in human monocytes. J. Immunol. 151: 2725-2732.
|
70 |
Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, et al. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472: 481-485.
DOI
|
71 |
Nan Y , Nan G, Z hang YJ. 2014. Interferon induction by RNA viruses and antagonism by viral pathogens. Viruses 6: 4999-5027.
DOI
|
72 |
Noppert SJ, Fitzgerald KA, Hertzog PJ. 2007. The role of type I interferons in TLR responses. Immunol. Cell Biol. 85: 446-457.
DOI
|
73 |
Nan Y, Ma Z, Wang R, Yu Y, Kannan H, Fredericksen B, et al. 2014. Enhancement of interferon induction by ORF3 product of hepatitis E virus. J. Virol. 88: 8696-8705.
DOI
|
74 |
Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. 2004. The RNA helicase RIG-I has an essential function in double-stranded RNAinduced innate antiviral responses. Nat. Immunol. 5: 730-737.
DOI
|
75 |
Nakhaei P, Genin P, Civas A, Hiscott J. 2009. RIG-I-like receptors: sensing and responding to RNA virus infection. Semin. Immunol. 21: 215-222.
DOI
|
76 |
Devhare PB, Chatterjee SN, Arankalle VA, Lole KS. 2013. Analysis of antiviral response in human epithelial cells infected with hepatitis E virus. PLoS One 8: e63793.
DOI
|
77 |
Gack MU, Shin YC, Joo CH, Urano T, Liang C, Sun L, et al. 2007. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 446: 916-920.
DOI
|
78 |
Oshiumi H, Miyashita M, Matsumoto M, Seya T. 2013. A distinct role of Riplet-mediated K63-linked polyubiquitination of the RIG-I repressor domain in human antiviral innate immune responses. PLoS Pathog. 9: e1003533.
DOI
|
79 |
Yu C, Boon D, McDonald SL, Myers TG, Tomioka K, Nguyen H, et al. 2010. Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences. J. Virol. 84: 11264-11278.
DOI
|
80 |
Wang J, Basagoudanavar SH, Wang X, Hopewell E, Albrecht R, Garcia-Sastre A, et al. 2010. NF-kappa B RelA subunit is crucial for early IFN-beta expression and resistance to RNA virus replication. J. Immunol. 185: 1720-1729.
DOI
|
81 |
Hardy MP, Owczarek CM, Jermiin LS, Ejdeback M, Hertzog PJ. 2004. Characterization of the type I interferon locus and identification of novel genes. Genomics 84: 331-345.
DOI
|
82 |
Vilcek J. 2003. Novel interferons. Nat. Immunol. 4: 8-9.
|
83 |
Nagashima S, Takahashi M, Jirintai, Tanaka T, Yamada K, Nishizawa T, et al. 2011. A PSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells. J. Gen. Virol. 92: 269-278.
DOI
|
84 |
Kenney SP, Pudupakam RS, Huang YW, Pierson FW, LeRoith T, Meng XJ. 2012. The PSAP motif within the ORF3 protein of an avian strain of the hepatitis E virus is not critical for viral infectivity in vivo but plays a role in virus release. J. Virol. 86: 5637-5646.
DOI
|
85 |
Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. 2015. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15: 405-414.
DOI
|
86 |
Xi Y, D ay S L, J ackson R J, R anasinghe C. 2012 . Role of novel type Iinterferon epsilon in viral infection and mucosal immunity. Mucosal Immunol. 5: 610-622.
DOI
|
87 |
Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. 2005. A critical function for type I interferons in cancer immunoediting. Nat. Immunol. 6: 722-729.
DOI
|
88 |
Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. 1999. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu. Rev. Immunol. 17: 189-220.
DOI
|
89 |
Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, et al. 2007. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. J. Immunol. 178: 7540-7549.
DOI
|
90 |
Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O'Garra A, Vicari A, et al. 2005. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J. Exp. Med. 201: 1157-1167.
DOI
|
91 |
Honda K, Taniguchi T. 2006. IRFs: master regulators of signalling by Toll-like receptors and cytosolic patternrecognition receptors. Nat. Rev. Immunol. 6: 644-658.
DOI
|
92 |
Xu L, Wang W, Li Y, Zhou X, Yin Y, Wang Y, et al. 2017. RIG-I is a key antiviral interferon-stimulated gene against hepatitis E virus regardless of interferon production. Hepatology 65: 1823-1839.
DOI
|
93 |
Shukla P, Nguyen HT, Torian U, Engle RE, Faulk K, Dalton HR, et al. 2011. Cross-species infections of cultured cells by hepatitis E virus and discovery of an infectious virus-host recombinant. Proc. Natl. Acad. Sci. USA 108: 2438-2443.
DOI
|
94 |
Fujita T, Onoguchi K, Onomoto K, Hirai R, Yoneyama M. 2007. Triggering antiviral response by RIG-I-related RNA helicases. Biochimie 89: 754-760.
DOI
|
95 |
Shukla P, Nguyen HT, Faulk K, Mather K, Torian U, Engle RE, et al. 2012. Adaptation of a genotype 3 hepatitis E virus to efficient growth in cell culture depends on an inserted human gene segment acquired by recombination. J. Virol. 86: 5697-5707.
DOI
|
96 |
Kenney SP, Meng XJ. 2015. The lysine residues within the human ribosomal protein S17 sequence naturally inserted into the viral nonstructural protein of a unique strain of hepatitis E virus are important for enhanced virus replication. J. Virol. 89: 3793-3803.
DOI
|
97 |
Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. 1998. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17: 1087-1095.
DOI
|
98 |
Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. 2005. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777.
DOI
|
99 |
Weaver BK, Kumar KP, Reich NC. 1998. Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1. Mol. Cell. Biol. 18: 1359-1368.
DOI
|
100 |
Au WC, Yeow WS, Pitha PM. 2 001. Analysis of functional domains of interferon regulatory factor 7 and its association with IRF-3. Virology 280: 273-282.
DOI
|
101 |
Hiscott J, Grandvaux N, Sharma S, Tenoever BR, Servant MJ, Lin R. 2003. Convergence of the NF-kappaB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann. NY Acad. Sci. 1010: 237-248.
DOI
|